Sino Biopharmaceutical (OTCMKTS:SBMFF) Sets New 12-Month High - Here's What Happened

Key Points

• Sino Biopharmaceutical's stock reached a new 52-week high of $0.95, closing at the same price after trading occurred.
• The stock's previous close was $0.89, indicating a significant increase in its market value.
• The company operates in various segments, offering a range of oncology and liver disease medications in the People's Republic of China.

Sino Biopharmaceutical (OTCMKTS:SBMFF - Get Free Report)'s stock price hit a new 52-week high on Wednesday . The stock traded as high as $0.95 and last traded at $0.95, with a volume of 100 shares. The stock had previously closed at $0.89.

Sino Biopharmaceutical Stock Up 6.8%

The company's 50 day moving average price is $0.70 and its two-hundred day moving average price is $0.53.

Sino Biopharmaceutical Company Profile

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.